About Aligos Therapeutics
Aligos Therapeutics is a company based in San Francisco (United States) founded in 2018.. Aligos Therapeutics has raised $225 million across 4 funding rounds from investors including Wellington, Boxer Capital and Logos Capital. The company has 70 employees as of December 31, 2024. Aligos Therapeutics offers products and services including ALG-000184 and ALG-055009. Aligos Therapeutics operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, NGM Biopharmaceuticals, Nimbus Therapeutics and Generate Biomedicines, among others.
- Headquarter San Francisco, United States
- Employees 70 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aligos Therapeutics, Inc.
-
Annual Revenue
$3.94 M-74.6as on Dec 31, 2024
-
Net Profit
$-131.21 M-49.65as on Dec 31, 2024
-
EBITDA
$-86.53 M-2.58as on Dec 31, 2024
-
Total Equity Funding
$225 M (USD)
in 4 rounds
-
Latest Funding Round
$105 M (USD), Post-IPO
Feb 11, 2025
-
Investors
Wellington
& 7 more
-
Employee Count
70
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Aligos Therapeutics
Aligos Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ALGS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Aligos Therapeutics
Aligos Therapeutics offers a comprehensive portfolio of products and services, including ALG-000184 and ALG-055009. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral small molecule for chronic hepatitis B virus infection
Oral small molecule for metabolic dysfunction-associated steatohepatitis
Unlock access to complete
Unlock access to complete
Funding Insights of Aligos Therapeutics
Aligos Therapeutics has successfully raised a total of $225M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $105 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $105.0M
-
First Round
First Round
(01 Jun 2018)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Post-IPO - Aligos Therapeutics | Valuation |
investors |
|
| Oct, 2023 | Amount | Post-IPO - Aligos Therapeutics | Valuation |
investors |
|
| Jan, 2020 | Amount | Series B - Aligos Therapeutics | Valuation | Wellington |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aligos Therapeutics
Aligos Therapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Wellington, Boxer Capital and Logos Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Private equity fund focused on the biotechnology sector
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aligos Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aligos Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aligos Therapeutics Comparisons
Competitors of Aligos Therapeutics
Aligos Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, NGM Biopharmaceuticals, Nimbus Therapeutics and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aligos Therapeutics
Frequently Asked Questions about Aligos Therapeutics
When was Aligos Therapeutics founded?
Aligos Therapeutics was founded in 2018.
Where is Aligos Therapeutics located?
Aligos Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Aligos Therapeutics?
Lawrence Blatt is the current CEO of Aligos Therapeutics.
Is Aligos Therapeutics a funded company?
Aligos Therapeutics is a funded company, having raised a total of $225M across 4 funding rounds to date. The company's 1st funding round was a Series B of $125M, raised on Jun 01, 2018.
How many employees does Aligos Therapeutics have?
As of Dec 31, 2024, the latest employee count at Aligos Therapeutics is 70.
What is the annual revenue of Aligos Therapeutics?
Annual revenue of Aligos Therapeutics is $3.94M as on Dec 31, 2024.
What does Aligos Therapeutics do?
Aligos Therapeutics was founded in 2018 and is headquartered in San Francisco, United States. Small molecule-based therapeutics are developed by the company to address hepatologic diseases and viral infections. Viral nucleic acids, encoded proteins, oncogenes, and resultant proteins are targeted through these treatments. Drugs have been created specifically for chronic hepatitis B, nonalcoholic steatohepatitis, and hepatocellular carcinoma.
Who are the top competitors of Aligos Therapeutics?
Aligos Therapeutics's top competitors include Moderna, Adaptive Biotechnologies and Nimbus Therapeutics.
What products or services does Aligos Therapeutics offer?
Aligos Therapeutics offers ALG-000184 and ALG-055009.
Is Aligos Therapeutics publicly traded?
Yes, Aligos Therapeutics is publicly traded on NASDAQ under the ticker symbol ALGS.
Who are Aligos Therapeutics's investors?
Aligos Therapeutics has 8 investors. Key investors include Wellington, Boxer Capital, Logos Capital, Vivo Capital, and Novo Holdings.
What is Aligos Therapeutics's ticker symbol?
The ticker symbol of Aligos Therapeutics is ALGS on NASDAQ.